EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Global Burden and Treatment Patterns of Treated Moderate-to-Severe Atopic Dermatitis: A Multi-Country Real-World Study

Stella Muthuri, Gabrielle Emanuel, Takeshi Nakahara, Silvia Calabria, John Paul Ekwaru, Ana Florea, Mark Lillie, Michael Duxbury, Dudan Zhang, Jifang Zhou, Huiping Wang, Hiroo Shimoda und 5 weitere

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s864

DOI: 10.25251/ws2b0v98 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Stella Muthuri und 16 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Moderate-to-severe atopic dermatitis (msAD) is associated with substantial disease burden, comorbidity, and treatment complexity. Real-world evidence describing the epidemiology and management of treated msAD across countries remains limited.

Objectives

To estimate the multinational prevalence of treated msAD, and describe baseline characteristics, comorbidities, and treatments among treated msAD patients.

Methods

This multinational retrospective cohort study used electronic medical records, claims, and mixed healthcare databases available between 2016 and 2024 from the United States (US), Canada, the United Kingdom (UK), Italy and China. Annual prevalent cohorts were identified using December 31 as the index date each year. Data were standardized to a common data model and analysed using a harmonized protocol. Eligible patients had ≥1 AD diagnosis within two years before the index date, ≥1 AD-related treatment within one year before index, and ≥12 months of baseline observation. Country-specific algorithms to identify treated msAD were developed based on literature review, local coding practices, treatment availability, and clinical input. Definitions incorporated severity markers such as msAD-related topical and systemic therapies, phototherapy, specialist care, hospitalization, and treatment intensity, depending on local data availability. As such, some country-specific algorithms may have preferentially identified patients with greater healthcare utilization, treated disease severity, and older age profiles, and findings should be interpreted accordingly. Annual age- and sex-standardized prevalence estimates were generated. Demographics and treatments were assessed during the 12 months before each index date (December 31), and comorbidities during the 24 months before index. Baseline characteristics for 2023 are presented.

Results

Between 2017 and 2024, prevalence increased from 2.7 to 6.4/1,000 persons in Canada and from 3.5 to 6.2/1,000 persons in the US. In the UK, prevalence remained stable, ranging from 5.8 to 7.7/1,000 persons and reaching 7.2/1,000 persons in 2024. Between 2017 and 2023, treated msAD prevalence in China ranged from 1.6 to 2.3, and in Italy, prevalence ranged from 0.1 to 0.4/1,000 persons. In 2023, median age ranged from 26yrs in the UK to 65yrs in the US (36yrs in Canada, 44yrs in China and 52yrs in Italy). Across countries with available capture, 63.8% (UK) to 92.1% (US) had ≥1 comorbidity and 20.1% (UK) to 40.1% (Canada) had ≥1 atopic-specific comorbidity. Italy was excluded because comorbidity capture was limited. Topical corticosteroids were the most used concomitant therapy (26.1% to 93.7%). Systemic corticosteroid use ranged from 19.5% in the UK to 80.2% in China. Available data and use of advanced therapies varied across countries; the UK was excluded because of limited capture. Biologic use ranged from 2.6% (China) to 13.9% (US), and oral Janus kinase inhibitor (JAKi) use from 0.6% (China) to 3.5% (Canada). In Italy, biologic and oral JAKi use was 56.0% and 21.0%, respectively.

Conclusions

This multinational real-world study demonstrated heterogeneity in treated msAD prevalence, patient characteristics, treatment patterns and data availability across healthcare systems. Findings should be interpreted in the context of country-specific case-identification algorithms and data capture, which may have influenced identified patient profiles. Across countries with available capture, high comorbidity burden and frequent systemic corticosteroid use suggest persistent unmet need among patients with treated msAD.

Zitieren

APA

Muthuri, S., Emanuel, G., Nakahara, T., Calabria, S., Ekwaru, J. P., Florea, A., Lillie, M., Duxbury, M., Zhang, D., Zhou, J., Wang, H., Shimoda, H., Herr, F., Qian, J., Droge, J., Kricorian, G., & Cordey, M. (2026). Global Burden and Treatment Patterns of Treated Moderate-to-Severe Atopic Dermatitis: A Multi-Country Real-World Study. SKIN The Journal of Cutaneous Medicine, 10(6), s864. https://doi.org/10.25251/ws2b0v98

Vancouver

Muthuri S, Emanuel G, Nakahara T, Calabria S, Ekwaru JP, Florea A, et al. Global Burden and Treatment Patterns of Treated Moderate-to-Severe Atopic Dermatitis: A Multi-Country Real-World Study. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s864. doi:10.25251/ws2b0v98

BibTeX
@article{Muthuri2026,
  author = {Muthuri, Stella and Emanuel, Gabrielle and Nakahara, Takeshi and Calabria, Silvia and Ekwaru, John Paul and Florea, Ana and Lillie, Mark and Duxbury, Michael and Zhang, Dudan and Zhou, Jifang and Wang, Huiping and Shimoda, Hiroo and Herr, Fiona and Qian, Joyce and Droge, Jessica and Kricorian, Gregory and Cordey, Myriam},
  title = {Global Burden and Treatment Patterns of Treated Moderate-to-Severe Atopic Dermatitis: A Multi-Country Real-World Study},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s864},
  doi = {10.25251/ws2b0v98}
}
Kostenlos starten →